Back to search

Article

Design, Synthesis and In Vitro Analysis of New Vemurafenib Analogs

2024-04-26

Abstract excerpt

Metastatic melanoma patients have a poor prognosis with poor responsiveness to chemotherapy. BRAF V600E mutations have been detected in ~40% of melanoma patients. Vemurafenib is an oral agent licensed for patients with BRAF V600E mutation-positive inoperable and metastatic melanoma, which already presents resistance that leads to patient relapse and the serious side effects. In our study, we synthesized 5 new vemu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7dade089-7d9b-5609-8973-996abd5dba44
DOI
10.20944/preprints202404.1757.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Design, Synthesis and In Vitro Analysis of New Vemurafenib AnalogsDOI 10.20944/preprints202404.1757.v1
Vemurafenib.Semantic proximity
Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity
The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.Semantic proximity
Vemurafenib: the road to personalized medicine in melanoma.Semantic proximity
Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Semantic proximity
Vemurafenib: the first drug approved for BRAF-mutant cancer.Semantic proximity
Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance.Semantic proximity
Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity
FDA approves vemurafenib for treatment of metastatic melanoma.Semantic proximity
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity
Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.Semantic proximity
Vemurafenib: a guide to its use in unresectable or metastatic melanoma.Semantic proximity
Select a neighboring publication to make it the new centre.